2 years ago
Prokarium Raises $30M for Oncology Therapeutics
Prokarium, a London-based biopharmaceutical company, has raised $30 million in funding to support clinical development and platform discovery.
ProblemLife Sciences/Biotechnology
"bladder cancer continues to be a costly and difficult-to-treat disease"
Solution
"develop advanced therapies, alternative to Bacillus Calmette-Guérin (BCG), by leveraging evolutionary advantages of a proprietary strain of Salmonella and combining them with bespoke synthetic circuits"
